Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 57-66 |
| Seitenumfang | 10 |
| Fachzeitschrift | European Journal of Pharmaceutics and Biopharmaceutics |
| Jahrgang | 126 |
| Frühes Online-Datum | 2 Dez. 2017 |
| Publikationsstatus | Veröffentlicht - Mai 2018 |
Abstract
The present overview deals with current approaches for the improvement of in vitro models for preclinical drug and formulation screening which were elaborated in a joint project at the Center of Pharmaceutical Engineering of the TU Braunschweig. Within this project a special focus was laid on the enhancement of skin and cornea models. For this reason, first, a computation-based approach for in silico modeling of dermal cell proliferation and differentiation was developed. The simulation should for example enhance the understanding of the performed 2D in vitro tests on the antiproliferative effect of hyperforin. A second approach aimed at establishing in vivo-like dynamic conditions in in vitro drug absorption studies in contrast to the commonly used static conditions. The reported Dynamic Micro Tissue Engineering System (DynaMiTES) combines the advantages of in vitro cell culture models and microfluidic systems for the emulation of dynamic drug absorption at different physiological barriers and, later, for the investigation of dynamic culture conditions. Finally, cryopreserved shipping was investigated for a human hemicornea construct. As the implementation of a tissue-engineering laboratory is time-consuming and cost-intensive, commercial availability of advanced 3D human tissue is preferred from a variety of companies. However, for shipping purposes cryopreservation is a challenge to maintain the same quality and performance of the tissue in the laboratory of both, the provider and the customer.
ASJC Scopus Sachgebiete
- Biochemie, Genetik und Molekularbiologie (insg.)
- Biotechnologie
- Pharmakologie, Toxikologie und Pharmazie (insg.)
- Pharmazeutische Wissenschaften
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: European Journal of Pharmaceutics and Biopharmaceutics, Jahrgang 126, 05.2018, S. 57-66.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung
}
TY - JOUR
T1 - Improved in vitro models for preclinical drug and formulation screening focusing on 2D and 3D skin and cornea constructs
AU - Beißner, Nicole
AU - Bolea Albero, Antonio
AU - Füller, Jendrik
AU - Kellner, Thomas
AU - Lauterboeck, Lothar
AU - Liang, Jinghu
AU - Böl, Markus
AU - Glasmacher, Birgit
AU - Müller-Goymann, Christel C.
AU - Reichl, Stephan
N1 - © 2017 Elsevier B.V. All rights reserved.
PY - 2018/5
Y1 - 2018/5
N2 - The present overview deals with current approaches for the improvement of in vitro models for preclinical drug and formulation screening which were elaborated in a joint project at the Center of Pharmaceutical Engineering of the TU Braunschweig. Within this project a special focus was laid on the enhancement of skin and cornea models. For this reason, first, a computation-based approach for in silico modeling of dermal cell proliferation and differentiation was developed. The simulation should for example enhance the understanding of the performed 2D in vitro tests on the antiproliferative effect of hyperforin. A second approach aimed at establishing in vivo-like dynamic conditions in in vitro drug absorption studies in contrast to the commonly used static conditions. The reported Dynamic Micro Tissue Engineering System (DynaMiTES) combines the advantages of in vitro cell culture models and microfluidic systems for the emulation of dynamic drug absorption at different physiological barriers and, later, for the investigation of dynamic culture conditions. Finally, cryopreserved shipping was investigated for a human hemicornea construct. As the implementation of a tissue-engineering laboratory is time-consuming and cost-intensive, commercial availability of advanced 3D human tissue is preferred from a variety of companies. However, for shipping purposes cryopreservation is a challenge to maintain the same quality and performance of the tissue in the laboratory of both, the provider and the customer.
AB - The present overview deals with current approaches for the improvement of in vitro models for preclinical drug and formulation screening which were elaborated in a joint project at the Center of Pharmaceutical Engineering of the TU Braunschweig. Within this project a special focus was laid on the enhancement of skin and cornea models. For this reason, first, a computation-based approach for in silico modeling of dermal cell proliferation and differentiation was developed. The simulation should for example enhance the understanding of the performed 2D in vitro tests on the antiproliferative effect of hyperforin. A second approach aimed at establishing in vivo-like dynamic conditions in in vitro drug absorption studies in contrast to the commonly used static conditions. The reported Dynamic Micro Tissue Engineering System (DynaMiTES) combines the advantages of in vitro cell culture models and microfluidic systems for the emulation of dynamic drug absorption at different physiological barriers and, later, for the investigation of dynamic culture conditions. Finally, cryopreserved shipping was investigated for a human hemicornea construct. As the implementation of a tissue-engineering laboratory is time-consuming and cost-intensive, commercial availability of advanced 3D human tissue is preferred from a variety of companies. However, for shipping purposes cryopreservation is a challenge to maintain the same quality and performance of the tissue in the laboratory of both, the provider and the customer.
KW - Anti-proliferation
KW - Cryopreservation
KW - Drug absorption
KW - DynaMiTES
KW - In silico models
KW - Numerical modeling
KW - Tissue-engineered cornea
KW - Tissue-engineered skin
KW - Toxicity
KW - Wound closure of cultivated tissue
UR - http://www.scopus.com/inward/record.url?scp=85039749502&partnerID=8YFLogxK
U2 - 10.1016/j.ejpb.2017.11.014
DO - 10.1016/j.ejpb.2017.11.014
M3 - Article
C2 - 29191717
AN - SCOPUS:85039749502
VL - 126
SP - 57
EP - 66
JO - European Journal of Pharmaceutics and Biopharmaceutics
JF - European Journal of Pharmaceutics and Biopharmaceutics
SN - 0939-6411
ER -